Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1

BACKGROUND: Eliglustat is a first-line oral treatment for adults with Gaucher disease type 1 who have an extensive, intermediate or poor CYP2D6 metabolizer phenotype (> 90% of patients). Whereas enzyme replacement therapy for Gaucher disease has been widely used for more than two decades, eliglus...

Descripción completa

Detalles Bibliográficos
Autores principales: Peterschmitt, M. Judith, Freisens, Selena, Underhill, Lisa H., Foster, Meredith C., Lewis, Grace, Gaemers, Sebastiaan J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555985/
https://www.ncbi.nlm.nih.gov/pubmed/31174576
http://dx.doi.org/10.1186/s13023-019-1085-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555985/
https://www.ncbi.nlm.nih.gov/pubmed/31174576
http://dx.doi.org/10.1186/s13023-019-1085-6

Ejemplares similares